Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
Identifieur interne : 000196 ( PascalFrancis/Curation ); précédent : 000195; suivant : 000197Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
Auteurs : Miriam E. R. Darnell [États-Unis] ; Kanta Subbarao [États-Unis] ; Stephen M. Feinstone [États-Unis] ; Deborah R. Taylor [États-Unis]Source :
- Journal of virological methods [ 0166-0934 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000794
Links to Exploration step
Pascal:04-0535983Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0535983</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0535983 INIST</idno>
<idno type="RBID">Pascal:04-0535983</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000794</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000196</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Method</term>
<term>Microbiology</term>
<term>Severe acute respiratory syndrome</term>
<term>Tissue culture</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Culture tissu</term>
<term>Microbiologie</term>
<term>Méthode</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-0934</s0>
</fA01>
<fA02 i1="01"><s0>JVMEDH</s0>
</fA02>
<fA03 i2="1"><s0>J. virol. methods</s0>
</fA03>
<fA05><s2>121</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DARNELL (Miriam E. R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SUBBARAO (Kanta)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FEINSTONE (Stephen M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TAYLOR (Deborah R.)</s1>
</fA11>
<fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>85-91</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18295</s2>
<s5>354000120328020120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0535983</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virological methods</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Culture tissu</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Tissue culture</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cultivo tejido</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Méthode</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Method</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Método</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Virologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Virology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Virología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fN21><s1>306</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000196 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000196 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:04-0535983 |texte= Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV }}
This area was generated with Dilib version V0.6.33. |